Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jul;10(2):e002340.
doi: 10.1136/openhrt-2023-002340.

Correct dosing, adherence and persistence of DOACs in atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis

Subo Emanuel  1 , Riyaz A Kaba  2   3   4 , Gayathri Delanerolle  5   6 , Benjamin C T Field  7   8 , Gregory Y H Lip  9   10 , Simon de Lusignan  5   11
Affiliations
Meta-Analysis

Correct dosing, adherence and persistence of DOACs in atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis

Subo Emanuel et al. Open Heart. 2023 Jul.

Abstract

Background: Chronic kidney disease (CKD) and atrial fibrillation (AF) are increasing in prevalence globally and share common risk factors.Our aim was to characterise real-world evidence on direct oral anticoagulant (DOAC) prescribing for people with AF and CKD, in terms of adherence, persistence and renal dose titration.

Methods: PubMed, EMBASE and CINAHL were searched from inception to June 2022. Our search terms included a combination of Medical Subject Headings (MeSH) terms and keywords including 'atrial fibrillation', 'chronic kidney disease', 'adherence', 'persistence', 'direct oral anticoagulants' and 'dosing'. Data extraction and quality assessment were undertaken by two reviewers independently. Meta-analyses for pooled estimates were performed using DerSimonian and Laird random-effects models. Age, sex, diabetes, hypertension and heart failure were chosen as variables of interest.

Results: From 19 studies, a total of 252 117 patients were included with CKD and AF. Meta-analysis was only possible in seven studies with 128 406 patients, five on DOAC dose titration and two on adherence. There were insufficient studies on persistence. Our meta-analysis of dosing showed that 68% of patients with CKD and AF had correct dosing. There was no evidence to show any association between correct DOAC dosing and variables of interest. Overall, 67% of patients were DOAC adherent.

Conclusion: Adherence and correct dosing of DOACs were suboptimal compared with other medications in the pooled studies with respect to CKD and AF. Thus, further research is required as the lack of generalisation of findings is a rate-limiting factor for improved DOAC management in AF and CKD.

Prospero registration number: CRD;42022344491.

Keywords: atrial fibrillation; drug monitoring; medication adherence; meta-analysis; systematic reviews as topic.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram of studies identified by searches, screened and included in final analysis.
Figure 2
Figure 2
Forest plot: correct direct oral anticoagulant dosing according to creatinine clearance.
Figure 3
Figure 3
Subanalysis correct direct oral anticoagulant dosing and sex.
Figure 4
Figure 4
Subanalysis correct direct oral anticoagulant dosing and age.
Figure 5
Figure 5
Subanalysis: correct direct oral anticoagulant dosing and hypertension (HTN).
Figure 6
Figure 6
Subanalysis: correct direct oral anticoagulant dosing and diabetes.
Figure 7
Figure 7
Subanalysis: correct dosing and heart failure (HF).
Figure 8
Figure 8
Forest plot showing adherence of direct oral anticoagulants in chronic kidney disease and atrial fibrillation.
See this image and copyright information in PMC

References

    1. Vora P, Morgan Stewart H, Russell B, et al. . Time trends and treatment pathways in prescribing individual oral anticoagulants in patients with nonvalvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States. Int J Clin Pract 2022;2022:6707985. 10.1155/2022/6707985 - DOI - PMC - PubMed
    1. Ruff CT, Giugliano RP, Braunwald E, et al. . Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62. 10.1016/S0140-6736(13)62343-0 - DOI - PubMed
    1. Granger CB, Alexander JH, McMurray JJV, et al. . Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92. 10.1056/NEJMoa1107039 - DOI - PubMed
    1. Giugliano RP, Ruff CT, Braunwald E, et al. . Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104. 10.1056/NEJMoa1310907 - DOI - PubMed
    1. NICE . Atrial fibrillation: diagnosis and management. 2021. Available: https://www.nice.org.uk/guidance/ng196

MeSH terms